A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03288545 |
Recruitment Status :
Active, not recruiting
First Posted : September 20, 2017
Last Update Posted : October 18, 2023
|
Sponsor:
Astellas Pharma Global Development, Inc.
Collaborators:
Merck Sharp & Dohme LLC
Seagen Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 31, 2026 |
Estimated Study Completion Date : | December 31, 2026 |